Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0,10%
1ย 094,90
+1,09
+0,10%
โ€”1ย 093,811ย 096,521ย 100,221ย 093,20โ€”โ€”
SIXC
Communications
SIXC
Communications
SIXC
+0,13%
609,57
+0,80
+0,13%
โ€”608,77608,77612,97608,77โ€”โ€”
SIXE
Energy
SIXE
Energy
SIXE
-1,24%
1ย 239,31
-15,50
-1,24%
โ€”1ย 254,811ย 253,011ย 253,871ย 226,33โ€”โ€”
SIXI
Industrials
SIXI
Industrials
SIXI
-0,72%
1ย 748,50
-12,61
-0,72%
โ€”1ย 761,111ย 764,271ย 766,881ย 745,39โ€”โ€”
SIXM
Financials
SIXM
Financials
SIXM
-0,12%
641,79
-0,79
-0,12%
โ€”642,58644,87648,48641,41โ€”โ€”
SIXR
Staples
SIXR
Staples
SIXR
-0,41%
847,62
-3,51
-0,41%
โ€”851,13855,66858,75845,56โ€”โ€”
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,37%
217,18
-0,80
-0,37%
โ€”217,98217,98218,65216,88โ€”โ€”
SIXT
Technology
SIXT
Technology
SIXT
+1,45%
3ย 258,27
+46,44
+1,45%
โ€”3ย 211,833ย 227,213ย 267,763ย 226,55โ€”โ€”
SIXU
Utilities
SIXU
Utilities
SIXU
-0,63%
942,99
-5,99
-0,63%
โ€”948,98948,58957,83941,97โ€”โ€”
SIXV
Health care
SIXV
Health care
SIXV
-0,20%
1ย 471,55
-2,97
-0,20%
โ€”1ย 474,521ย 479,031ย 481,041ย 469,17โ€”โ€”
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,49%
2ย 403,80
+12,09
+0,49%
โ€”2ย 392,122ย 396,952ย 421,222ย 382,32โ€”โ€”
HALO:NASDAQ
Halozyme Therapeutics, Inc.
64,28ย USD
+0,97%
(+0,62) 1D
1-ะผะฐะน, 15:09:58 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HALO...
Open
63,48ย USD
High
64,31ย USD
Low
62,38ย USD
Mkt. cap
7,61ย ะผะปะด
Avg. vol.
1,46ย ะผะปะฝ
Volume
477,93ย ะผะธาฃ
P/E ratio
25,13
52-wk high
82,22ย USD
52-wk low
47,50ย USD
EPS
2,56ย USD
Beta
1,03
Shares outstanding
118,47ย ะผะปะฝ
No. of employees
423
News stories
From sources across the web
The Pharma Letter
The Pharma Letter
·
8 ัะฐะฐั‚ ะผัƒั€ัƒะฝ
Halozyme appoints J&J veteran as finance chief
Yahoo Finance
Yahoo Finance
·
22 ัะฐะฐั‚ ะผัƒั€ัƒะฝ
Halozyme to Report First Quarter 2026 Financial and Operating Results
Stock Titan
Stock Titan
·
22 ัะฐะฐั‚ ะผัƒั€ัƒะฝ
Halozyme sets May 11 earnings release, call after market close
Minichart
Minichart
·
1 ะบาฏะฝ ะผัƒั€ัƒะฝ
Halozyme Therapeutics Appoints Darren Snellgrove as Chief Financial Officer in April 2026
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
Headquartersะกะฐะฝ ะ”ะธะตะณะพ, ะšะฐะปะธั„ะพั€ะฝะธั, ะะผะตั€ะธะบะฐ ะšะพัˆะผะพ ะจั‚ะฐั‚ั‚ะฐั€ั‹
Sector-
Websitehalozyme.com
Next call 10 ะบาฏะฝะดำฉะฝ ะบะธะนะธะฝ
11-ะผะฐะน, ะดาฏะน., 16:30
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (1,52 est.)USD
Revenue / Estimate
-/ (359,05ย ะผะปะฝ est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ะถ. ะผะฐั€.
2025-ะถ. ะธัŽะฝ.
2025-ะถ. ัะตะฝ.
2025-ะถ. ะดะตะบ.
Revenue
264,86ย ะผะปะฝ
325,72ย ะผะปะฝ
354,26ย ะผะปะฝ
451,77ย ะผะปะฝ
Cost of goods sold
63,20ย ะผะปะฝ
46,36ย ะผะปะฝ
72,49ย ะผะปะฝ
110,67ย ะผะปะฝ
Cost of revenue
63,20ย ะผะปะฝ
46,36ย ะผะปะฝ
72,49ย ะผะปะฝ
110,67ย ะผะปะฝ
Research and development expenses
-
17,54ย ะผะปะฝ
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
42,36ย ะผะปะฝ
41,61ย ะผะปะฝ
46,09ย ะผะปะฝ
63,33ย ะผะปะฝ
Operating expense
60,12ย ะผะปะฝ
76,92ย ะผะปะฝ
63,85ย ะผะปะฝ
86,70ย ะผะปะฝ
Total operating expenses
123,33ย ะผะปะฝ
123,28ย ะผะปะฝ
136,34ย ะผะปะฝ
197,37ย ะผะปะฝ
Operating income
141,54ย ะผะปะฝ
202,44ย ะผะปะฝ
217,92ย ะผะปะฝ
254,40ย ะผะปะฝ
Other non operating income
-
6,89ย ะผะปะฝ
-
-
EBT including unusual items
143,83ย ะผะปะฝ
204,94ย ะผะปะฝ
218,96ย ะผะปะฝ
-100,85ย ะผะปะฝ
EBT excluding unusual items
142,12ย ะผะปะฝ
204,94ย ะผะปะฝ
218,96ย ะผะปะฝ
251,58ย ะผะปะฝ
Income tax expense
25,73ย ะผะปะฝ
39,78ย ะผะปะฝ
43,73ย ะผะปะฝ
40,74ย ะผะปะฝ
Effective tax rate
17,89%
19,41%
19,97%
-40,40%
Other operating expenses
-
-
-
-
Net income
118,10ย ะผะปะฝ
165,16ย ะผะปะฝ
175,22ย ะผะปะฝ
-141,59ย ะผะปะฝ
Net profit margin
44,59%
50,71%
49,46%
-31,34%
Earnings per share
1,11
1,54
1,72
-0,24
Interest and investment income
5,11ย ะผะปะฝ
-
5,33ย ะผะปะฝ
2,09ย ะผะปะฝ
Interest expense
-4,52ย ะผะปะฝ
-4,39ย ะผะปะฝ
-4,30ย ะผะปะฝ
-4,91ย ะผะปะฝ
Net interest expenses
584,00ย ะผะธาฃ
-4,39ย ะผะปะฝ
1,04ย ะผะปะฝ
-2,82ย ะผะปะฝ
Depreciation and amortization charges
-
-
-
-
EBITDA
160,48ย ะผะปะฝ
221,44ย ะผะปะฝ
236,84ย ะผะปะฝ
279,08ย ะผะปะฝ
Gain or loss from assets sale
-
-
-
2,62ย ะผะปะฝ
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer